Method for diagnosing a person having multiple sclerosis

Method for diagnosing a person having cancer or being at risk of aquiring cancer, comprising the following steps:

• providing a sample of a body fluid or tissue from said person, said sample containing at least one of the wild type SCF-Apoptosis-Response Gene- (wt-SARG-1-) protein and nucleic acids encoding wt-SARG-1, if taken from a person not having cancer or being at risk of aquiring cancer, comprising
• detecting the presence of wt-SARG-1-protein or nucleic acids encoding wt-SARG-1 in said sample and
• diagnosing cancer or a risk of aquiring cancer, if wt-SARG-1-protein or nucleic acids encoding wt-SARG-1 are not present in said sample.

Method according to 9 or 10, wherein said detecting the presence of wt-SARG-1-protein or nucleic acids encoding wt-SARG-1 in said sample further comprises detecting the presence of a non-wt-form of SARG-1 or SARG-1-protein.

Nucleic acid molecule comprising a sequence according to Seq.ID.No. 1.

Nucleic acid molecule comprising a sequence according to Seq.ID.No. 1, wherein one nucleic acid residue is exchanged by a different nucleic acid residue, preferably said exchange results in a different SARG-1-protein amino acid sequence.

Polypeptide comprising an amino acid sequence according to Seq.ID.No. 2.

Polypeptide comprising an amino acid sequence according to Seq.ID.No. 2, wherein one amino acid residue is exchanged or deleted.

Method for making an antibody preparation comprising administering a polypeptide selected from the group consisting of a polypeptide comprising an amino acid sequence according to Seq.ID.No. 2 or a mutated form thereof, to an animal, allowing said animal to generate antibodies against said polyppptide, extracting antibody-containing body fluids or tissue from said animal and preparing an antibody preparation against said polypeptide from said body fluids or tissue.

Method for making an antibody preparation comprising administering a polypeptide selected from the group consisting of a polypeptide comprising an amino acid sequence according to Seq.ID.No. 2 or a mutated form thereof, to an animal, allowing said animal to generate antibodies against said polypeptide, removing the spleen of said animal, preparing fusion cells of said spleen with suitable hybridoma generating cells, generating hybridoma cells producing monoclonal antibodies against said polypeptide, cloning and culturing said hybridoma cells, thereby expressing monoclonal antibodies, and preparation of said monoclonal antibodies.

A transgenic non-human animal comprising a mutated or deleted SARG-1, wherein said mutated or deleted SARG-1 has been introduced into the genome of said animal and stably integrated therein by recombinant nucleic acid techniques.

Use of a SARG-1 binding protein to modulate activity of SARG-1 or SARG-1 mutants.

Use of SARG-1 or fragments thereof to modulate activity of SARG-1 binding proteins.

Use of a SARG-1 binding protein for the preparation of a medicine to treat or prevent multiple sclerosis.

Use of SARG-1 or a fragment thereof for the preparation of a medicine to treat or prevent multiple sclerosis.

use of a SARG-1 binding protein for the preparation of a medicine to treat or prevent cancer, preferably myeloproliferative disorders, polycythaemia, myelodysplasia and myeloid leukaemia, especially acute myeloid leukaemia.

Use of SARG-1 or a fragment thereof for the preparation of a medicine to treat or prevent cancer, preferably myeloproliferative disorders, polycythaemia, myelodysplasia and myeloid leukaemia, especially acute myeloid leukaemia.